Advantage Marketing Systems Introduces Revolutionary All Natural External Pain Relief Gel.

Business Editors, Health & Medical Writers

OKLAHOMA CITY--(BW HealthWire)--April 12, 2000

Advantage Marketing Systems, Inc. ("AMS") (AMEX:AMM) today announced the successful launch of its all natural, instant pain relief gel, made with dietary Methylsulfonylmethane ("MSM") under the trade name MSM Complex7.

This breakthrough product is designed to address what the American Medical Association has described as an epidemic of pain. According to The Management of Pain, a two-volume reference book for physicians, more than one-third of the American population have chronic painful conditions and of those, half or more are partially or totally disabled for periods of days, weeks, months, years or permanently. Arthritis alone afflicts more than 43 million individuals or one out of every six Americans.

Many years of clinical use at Oregon Health Sciences University has demonstrated that MSM provides a number of important pain relief and anti-inflammatory benefits including inhibition of pain impulses along nerve fibers, lessening of inflammation, increase in blood supply and reduction of muscle spasms. Among its many uses, it has been proven an effective solution to the pain associated with musculoskeletal system disorders (osteoarthritis), athletic injuries and repetitive strain injuries.

"We are pleased to have a unique proprietary product that can make such a significant difference in so many people's lives," said AMS founder and CEO, John W. Hail. "MSM Complex7 has been our most successful product introduction since AM-300. In just two months MSM Complex7 sales have exploded, making it one of our top ten products."

AMS markets more than 100 natural nutritional supplements, weight management products, skin and hair care products and cosmetics based on herbal-based proprietary product formulations. The Company's products are distributed by more than 71,000 independent distributors.

For more information, visit the Company's web site at www.amsonline.com.

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Certain, but not necessarily all, of such forward-looking statements can be identified by the use of forward-looking terminology such as "anticipates," "believes," "expects," "may," "will," or "should" or other variations thereon, or by discussions of strategies that involve risks and uncertainties. The actual results of the Company or industry results may be materially different from any future results expressed or implied by such forward-looking statements. The Food and Drug Administration has not evaluated these statements. This product is not intended to diagnose, treat, cure or prevent any disease.